Connective tissue disease（CTD） is an autoimmune disease involving multiple organs and systems

and when the lesion involves the respiratory system

it mostly manifests as interstitial lung changes

and connective tissue disease-associated interstitial lung disease（CTD-ILD） is one of the important causes of poor patient prognosis. Clinical guidelines or consensus on the treatment of CTD-ILD are still lacking. Steroids and immunosuppressants are the first-line drugs for the treatment of CTD-ILD

and timely initiation of antifibrotic therapy is the key link to controlling disease progression. Pirfenidone（PFD） and nintedanib are 2 new antifibrotic drugs

both approved for the treatment of idiopathic pulmonary fibrosis（IPF）. In recent years

the efficacy of these drugs in the clinical treatment of CTD-ILD has been reported in the literature. Therefore

this paper reviews the current status of clinical studies on PFD and nidanib in the treatment of CTD-ILD.